Tag Archives: biopharmaceutical
Hotspots in Biopharma Digital Marketing Innovation
The rapid growth of digital, mobile and related technologies has transformed the global communications paradigm, and with it, changed the ways in which consumers and professionals access information. In case of the biopharmaceutical and medical device industry, the development of
Creating and Maintaining a Strategic KOL Management and Engagement System
Across the pharmaceutical sector, regulatory and access issues have reshaped interactions with Key Opinion Leaders (KOLs). And with KOL interactions affecting everything from clinical development to product launch, the issue of strategically managing these critical exchanges looms large for small
Patient Centricity Has Arrived. Bigger Question: Where Is It Headed?
Patients have always been on pharma’s radar, though it has historically been as a target of marketing (the most obvious being Direct to Consumer (DTC) advertising). But now under the banner of Patient Centricity, pharma companies large and small are
Best Practices in Lifecycle Management: Maximizing the Potential of Mature Brands
As many drugs are reaching the patent cliff, strategies to extend the commercial life of mature brands is critical to today’s pharmaceutical industry. Used correctly, lifecycle management strategies can add as many as 10 years and billions of dollars to
Medical Affairs Consortium: Impact Measures, Globalization & Compliance
On November 6, 2014 Best Practices, LLC hosted the 1st roundtable of the 2014-2015 Medical Affairs’ Consortium. The roundtable brought together leaders from: Baxter, Crescendo, Eli Lilly, Genentech, Incyte Corporation, Jazz Pharmaceuticals, Pfizer, Santen Inc., Teva, and Upsher-Smith. Leaders from
Thou Shalt Build Credibility But Plan for the Worst
As pharma companies plan for the launch of new products, much of the discussion centers around how to position a new drug or device to the rest of the world. Still, much of that same planning can be internalized and
Competitive Intelligence Guidelines & Policies Keeping Companies in the Safety Zone
Competitive Intelligence (CI) groups are instrumental in helping world-class companies to anticipate and respond strategically to external change. Primary and secondary competitive intelligence research helps organizations to improve their chances for success in today’s competitive business environment. While there are
Success Factors & Lessons Learned in New Product Launches
In today’s competitive & crowded marketplace, biopharmaceutical companies are investing more and more resources to develop and launch new products for cardiovascular therapeutic areas. Consequently, recent industry product launches have produced both noteworthy failures and successes. It is now, more
Optimizing Government Affairs & Public Policy Groups’ Structures & Operations
Public Policy and Government Affairs functions within the pharmaceutical industry have become increasingly critical during this period of political, economic, and social turbulence. With both functions involved in essential areas such as legislative affairs, reimbursement, and regulatory, it’s important for
SPECIAL: Highlights from Medical Affairs Consortium 3rd Roundtable
The Medical Affairs function is constantly changing & leaders are being presented with various obstacles and hurdles they must overcome. One of the key areas that leaders have been struggling with recently is effective thought leader management. In order to